- Design
- Systematic review and meta-analysis of randomised trials
- Population
- 482 long-term care residents with moderate to severe dementia and mild to moderate pain
- Primary outcome
- Observed pain score
- Effect
- SMD −0.14 (95% CI −0.39 to 0.11); I² = 6%
This systematic review and meta-analysis, published in October, found four randomised trials in the US and Europe enrolling 482 long-term care residents with moderate to severe dementia and mild to moderate pain. Paracetamol was given three to four times a day, 2.5 to 3 g in total, for 4 to 13 weeks, against placebo in three trials and usual care in one. Pain was measured with observational dementia pain scales.
Scheduled paracetamol did not significantly reduce pain (standardised mean difference −0.14, 95% CI −0.39 to 0.11; I² = 6%; moderate certainty). The one trial assessing quality of life found no difference. Adverse events were inconsistently reported.
Regular paracetamol is widely prescribed across care homes as a default first step, often indefinitely. This suggests that for residents with advanced dementia and mild to moderate pain, a standing prescription may add pill burden without measurable benefit. It does not mean paracetamol never helps: the trials were short, the pain was mild to moderate, and observational scales may miss benefit. It is a reason to review standing prescriptions and treat pain from a specific cause.
- Review standing regular paracetamol prescriptions for care-home residents with advanced dementia.
- Reassess pain with an observational scale before continuing or stopping regular analgesia.
- Target treatment at a specific cause of pain, such as osteoarthritis flare or a pressure area.
- Consider as-needed rather than regular dosing where benefit is unclear.
- Keep total daily paracetamol within safe limits for frail, low-weight residents.
Why it matters
It challenges a near-universal care-home habit that adds tablets to already long medication lists.
Don't overread it
Short trials in mild to moderate pain do not show that paracetamol is ineffective for all pain in dementia.
The statistics, in plain English
An SMD of −0.14 is a very small effect, and the interval crosses zero, so the trials could not show any benefit. Low heterogeneity (I² = 6%) means the four trials agreed. With only 482 residents, a small real benefit cannot be ruled out.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for geriatrics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free